ABSTRACT
Two cis-ß-MnIIISALPN catalysts were synthesised and tested in the Mukaiyama-Isayama hydration of α,ß-unsaturated esters. The MnIIIEtOSALPN(acac) complex 7 is the most active and catalyses hydration with little or no detectable undesired alkene reduction. This catalyst is superior for alkene hydration compared to the originally reported Mn(dpm)3 catalyst.
ABSTRACT
This research aimed to develop new tumor targeted theranostic agents taking advantage of the similarities in coordination chemistry between technetium and rhenium. A γ-emitting radioactive isotope of technetium is commonly used in diagnostic imaging, and there are two ß- emitting radioactive isotopes of rhenium that have the potential to be of use in radiotherapy. Variants of the 6-hydrazinonicotinamide (HYNIC) bifunctional ligands have been prepared by appending thioamide functional groups to 6-hydrazinonicotinamide to form pyridylthiosemicarbazide ligands (SHYNIC). The new bidentate ligands were conjugated to the tumor targeting peptides Tyr3-octreotate and cyclic-RGD. The new ligands and conjugates were used to prepare well-defined {MâO}3+ complexes (where M = 99mTc or natRe or 188Re) that feature two targeting peptides attached to the single metal ion. These new SHYNIC ligands are capable of forming well-defined rhenium and technetium complexes and offer the possibility of using the 99mTc imaging and 188/186Re therapeutic matched pairs.
Subject(s)
Coordination Complexes/chemical synthesis , Peptides, Cyclic/chemical synthesis , Rhenium/chemistry , Semicarbazones/chemical synthesis , Coordination Complexes/chemistry , Drug Stability , Hydrazines/chemistry , Ligands , Peptides, Cyclic/chemistry , Pyridines/chemistry , Semicarbazones/chemistry , Theranostic Nanomedicine , Thioamides/chemistryABSTRACT
With the aim of preparing hypoxia-selective imaging and therapeutic agents, technetium(I) and rhenium(I) tricarbonyl complexes with pyridylhydrazone, dipyridylamine, and pyridylaminocarboxylate ligands containing nitrobenzyl or nitroimidazole functional groups have been prepared. The rhenium tricarbonyl complexes were synthesized with short reaction times using microwave irradiation. Rhenium tricarbonyl complexes with deprotonated p-nitrophenyl pyridylhydrazone ligands are luminescent, and this has been used to track their uptake in HeLa cells using confocal fluorescent microscopy. Selected rhenium tricarbonyl complexes displayed higher uptake in hypoxic cells when compared to normoxic cells. A (99m)Tc tricarbonyl complex with a dipyridylamine ligand bearing a nitroimidazole functional group is stable in human serum and was shown to localize in a human renal cell carcinoma (RCC; SK-RC-52) tumor in a mouse.
Subject(s)
Hypoxia , Organometallic Compounds/pharmacokinetics , Rhenium/pharmacokinetics , Technetium/pharmacokinetics , Animals , Cell Line, Tumor , Diagnostic Imaging , Electrochemical Techniques , HeLa Cells , Humans , Ligands , Luminescence , Mice , Mice, Inbred BALB C , Mice, Nude , Microscopy, Fluorescence , Models, Molecular , Molecular Structure , Organometallic Compounds/chemical synthesis , Organometallic Compounds/chemistry , Rhenium/chemistry , Technetium/chemistry , Tissue DistributionABSTRACT
Alzheimer's disease is associated with the presence of insoluble protein deposits in the brain called amyloid plaques. The major constituent of these deposits is aggregated amyloid-ß peptide. Technetium-99m complexes that bind to amyloid-ß plaques could provide important diagnostic information on amyloid-ß plaque burden using Single Photon Emission Computed Tomography (SPECT). Tridentate ligands with a stilbene functional group were used to form complexes with the fac-[M(I)(CO)3](+) (M = Re or (99m)Tc) core. The rhenium carbonyl complexes with tridentate co-ligands that included a stilbene functional group and a dimethylamino substituent bound to amyloid-ß present in human frontal cortex brain tissue from subjects with Alzheimer's disease. This chemistry was extended to make the analogous [(99m)Tc(I)(CO)3](+) complexes and the complexes were sufficiently stable in human serum. Whilst the lipophilicity (log D7.4) of the technetium complexes appeared ideally suited for penetration of the blood-brain barrier, preliminary biodistribution studies in an AD mouse model (APP/PS1) revealed relatively low brain uptake (0.24% ID g(-1) at 2 min post injection).
Subject(s)
Amyloid beta-Peptides/metabolism , Organometallic Compounds/chemistry , Organometallic Compounds/metabolism , Rhenium/chemistry , Technetium/chemistry , Animals , Brain/diagnostic imaging , Brain/metabolism , Drug Stability , Humans , Mice , Organometallic Compounds/pharmacokinetics , Plaque, Amyloid/diagnostic imaging , Plaque, Amyloid/metabolism , Protein Binding , Tissue Distribution , Tomography, Emission-Computed, Single-Photon , Tomography, X-Ray ComputedABSTRACT
A series of selenophene analogues of the thiophene-containing antihypertensives milfasartan and eprosartan were prepared and tested for AT(1) receptor antagonist properties. All four selenophene compounds proved to be potent AT(1) receptor antagonists, with pK(B) estimates indicating that these selenides are at least as effective as the thiophene parent compounds at blocking AT(1) receptor mediated responses. These results reveal that replacement of sulfur with selenium in thiophene-containing sartans does not interfere with sartan activity.
